New hope for hemophilia patients facing surgery: clotting factor trial underway
NCT ID NCT05935358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a recombinant factor VIII product called Nuwiq can safely prevent bleeding during major surgery in people with severe hemophilia A who are already on emicizumab. About 28 male patients aged 12 and older will take part. The main goal is to see if the treatment successfully controls bleeding during and after the operation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliera Pugliese Ciaccio
RECRUITINGCatanzaro, Italy
-
Azienda Ospedaliero Universitaria Careggi - Centro Emofilia
RECRUITINGFlorence, Italy
-
CHRU de Tours
RECRUITINGTours, France
-
CHU de Nantes Hôtel-Dieu
RECRUITINGNantes, France
-
Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia
RECRUITINGSkopje, North Macedonia
-
Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital
RECRUITINGMilan, Italy
-
Christian Medical College Vellore
RECRUITINGVellore, Tamil Nadu, India
-
Clinical Center for Serbia Belgrade
RECRUITINGBelgrade, Serbia
-
Gerinnungszentrum Rhein-Ruhr
RECRUITINGDuisburg, Germany
-
Helsinki University Hospital
RECRUITINGHelsinki, Finland
-
Hospital Universitario La Paz
RECRUITINGMadrid, Spain
-
Hospital Universitario Virgen del Rocio
RECRUITINGSeville, Spain
-
St. James's University Hospital
NOT_YET_RECRUITINGLeeds, United Kingdom
-
St. John's Medical College Hospital
RECRUITINGBengaluru, India
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
University Hospital Centre Zagreb
RECRUITINGZagreb, Croatia
-
Universitätsklinikum Hamburg Eppendorf (UKE)
RECRUITINGHamburg, Germany
-
Vivantes Klinikum im Friedrichshein (KFH)
RECRUITINGBerlin, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- New clotting factor aims to cut bleeding episodes in severe hemophilia a
- New clotting factor aims to stop bleeding in severe hemophilia a
- New clotting factor shows promise for hemophilia a bleeds
- Blood test may predict bleeding risk in hemophilia a patients on emicizumab